Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a "Western-style diet" by increasing PPAR α and γ expression and reducing TC, MMP-9, and Cat S levels

Acta Pharmacol Sin. 2010 Oct;31(10):1350-8. doi: 10.1038/aps.2010.109. Epub 2010 Sep 13.

Abstract

Aim: The examine the cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice (ApoE-/- mice) fed a "Western-style diet" and the effect of simvastatin intervention.

Methods: Male ApoE-/- mice (n=36) were fed a "Western-style diet" from the age of 8 weeks. After 16 weeks, they were randomly given either simvastatin (25 mg·kg⁻¹·d⁻¹) or normal saline (control group) by gavage for 8, 16, or 24 weeks. The left ventricular (LV) wall thickness and diameter of the myocardial cells were determined with Hematoxylin-Eosin stain, and the level of fibrosis of the myocardial matrix was assessed with Masson stain. Real-time quantitative polymerase chain reaction and Western blotting analysis were used to determine the mRNA and protein expression of matrix metalloproteinase-9 (MMP-9), Cathepsin S (Cat S), and the peroxisome proliferator-activated receptors (PPARs) in the myocardium of ApoE-/- mice.

Results: ApoE-/- mice fed a "Western-style diet" showed an significant age-dependent increase in total cholesterol (TC), LV wall thickness, myocardial cell diameter and LV collagen content (P<0.05). The simvastatin treatment group showed significantly reduced LV wall thickness, myocardial cell diameters and LV collagen content at 40 weeks when compared with the control group (P<0.05). Furthermore, treatment with simvastatin also significantly inhibited the mRNA and protein expressions of MMP-9 and Cat S as well as increased the mRNA and protein expressions of PPAR alpha and PPAR gamma at 32 and 40 weeks compared with the control group (P<0.05).

Conclusion: ApoE-/- mice fed a "Western-style diet" had cardiac hypertrophy and fibrosis, which worsened with age. Simvastatin treatment inhibits the development of cardiac hypertrophy and fibrosis, and this effect may be mediated through increased levels of PPAR alpha and PPAR gamma and reduced levels of TC, MMP-9, and Cat S.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apolipoproteins E / genetics*
  • Cardiomegaly / metabolism
  • Cardiomegaly / pathology
  • Cardiomegaly / prevention & control*
  • Cathepsins / metabolism*
  • Cholesterol / metabolism*
  • Diet*
  • Dietary Fats / administration & dosage
  • Fibrosis
  • Heart Ventricles / drug effects
  • Heart Ventricles / pathology
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Male
  • Matrix Metalloproteinase 9 / metabolism*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • PPAR alpha / metabolism
  • PPAR gamma / metabolism
  • Peroxisome Proliferator-Activated Receptors / metabolism*
  • Simvastatin / pharmacology*
  • Simvastatin / therapeutic use

Substances

  • Apolipoproteins E
  • Dietary Fats
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • PPAR alpha
  • PPAR gamma
  • Peroxisome Proliferator-Activated Receptors
  • Cholesterol
  • Simvastatin
  • Cathepsins
  • cathepsin S
  • Matrix Metalloproteinase 9